Igor Gennadjevich Khamin

Igor Gennadjevich Khamin

Auto-generated profile, based on publicly available information

Igor Gennadjevich Khamin

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2022 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venyov
D. A. Venyov
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
MSM. N. Sadovskaya
M. N. Sadovskaya
OGO. V. Goronkova
O. V. Goronkova
ЮОЮ. В. Ольшанская
Ю. В. Ольшанская
Over the past years, the outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to the use of intensive chemotherapy, more effective supportive therapy, and the availability of allogeneic hematopoietic stem cell transplantation. This article presents the outcomes of children with AML treated in accordance with the AML-MM-2006 protocol. Our study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 233 patients with a median age of 6.5 years (7 days – 18 years) who were stratified into the following risk groups: standard risk, intermediate risk, and high risk. The 5-year event-free survival (EFS) was 0.64 ± 0,14, 0.49 ± 0.05, and 0.43 ± 0.05 for standard-risk (n = 12), intermediate-risk (n = 106), and high-risk (n = 115) patients, respectively (p = 0.14), while the 5-year overall survival (OS) was 1.0 year, 0.7 ± 0.05 and 0.55 ± 0.05, respectively (p = 0.001). The OS in the entire cohort was 0.68 ± 0.032. Factors associated with poor prognosis included hyperleukocytosis, the presence of extramedullary lesions, and age 1 year. The overall survival rates in these patient groups were 0.55 ± 0.08, 0.39 ± 0.09 and 0.49 ± 0.08, respectively. The worst prognosis was for patients with monosomy 7 and t(7;12) whose OS rates were 0.25 ± 0.2 and 0.4 ± 0.2, respectively. For non-responders and patients with relapsed AML, the OS was 0.33 ± 0.08 and 0.54 ± 0.06, respectively. Early death (before remission could be achieved) occurred in 4% of patients, and 3.8% of patients died in first remission. Sixtytwo percent of deceased patients died of disease progression. In the entire cohort of patients, the five-year EFS was 0.53 ± 0.047, the cumulative risk of relapse after 3 years of remission was 40%, the confidence interval was 23–89%.

20 April 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
NBN. A. Bolshakov
N. A. Bolshakov
AAA. Yu. Artemov
A. Yu. Artemov
AVA. M. Vorochai
A. M. Vorochai
IKI. G. Khamin
I. G. Khamin
MTM. V. Tikhonova
M. V. Tikhonova
AKA. I. Karachunsky
A. I. Karachunsky
Aim: analysis of own experience in endoprosthesis reconstruction of the knee for children and adolescents with primary bone tumors. The article reports the results of 65 endoprosthesis reconstruction of the knee joint in children and adolescents with oncological pathology for a 5-year period (2012-2017). The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. Evaluation of functional results was performed using the MSTS scale 3 months after the operation. Postoperative complications were analyzed according to the Henderson classification. The average indicator of the functional rate after operative treatment, according to the MSTS scale, was 76%. The most common postoperative complications were structural failures (7.6%) and infectious complications (6.2%). Overall survival in the largest group of patients with osteosarcoma (56 patients) was 82 ± 12%, event-free survival 37 ± 12%. The use of individual expandable endoprostheses makes it possible to perform operations for patients with skeletal immaturity. Endoprosthesis replacement provide good oncological and functional results, and also contribute to the most adequate social adaptation of the child.

2 July 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EKE. E. Kurnikova
E. E. Kurnikova
IKI. G. Khamin
I. G. Khamin
VSV. V. Shchukin
V. V. Shchukin
TST. V. Shamanskaya
T. V. Shamanskaya
MFM. S. Fadeeva
M. S. Fadeeva
PTPavel Trakhtman
Pavel Trakhtman
Polychemotherapy, accompanied by autologous hematopoietic stem cell transplantation, can improve the results of long-term survival of patients with cancer and some non-cancer diseases. Mobilizing and collecting hematopoietic stem cells in children with very low body weight can be a difficult task. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. 19 children with extremely low body weight was included in the current study. The median age was 8 (5–14) months, the median of body weight 7.5 (5.8–8.8) kg. Apheresis was performed in an ICU, using sedative therapy and in compliance with the conditions for the prevention of anemia, hypovolemia, hypothermia. 19 hematopoietic stem cell apheresis were performed using the Spectra Optia MNC separator program. Mobilization of CD34+ cells was performed with filgrastim; three children were additionally given plerixaphor. All 19 hematopoietic stem cell apheresis were successful: the median of collected CD34+ cells was 18.7 × 106/kg (8.6– 60.6 × 106/kg), the median apheresis duration was 204 (161–351) min. Serious side effects during apheresis were not recorded, however, in 6 children (31%) we encountered difficulties in the process of installing central venous access. The collection of hematopoietic stem cells for the future high-dose chemotherapy with autologous hematopoietic stem cells is a feasible task even for very young children with extremely low body weight. Correct preparation for manipulation, taking into account all possible risk factors and technical features, can avoid serious complications.

28 May 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
NANataliya A. Andreeva
Nataliya A. Andreeva
EBE.O. Bezdolnova
E.O. Bezdolnova
DKDenis Kachanov
Denis Kachanov
ASA.B. Smirnova
A.B. Smirnova
TST.V. Shamanskaya
T.V. Shamanskaya
Neuroblastoma (NB) is the most common extracranial solid embryonic tumor in children. The age of patient, the prevalence of the tumor process and the molecular genetic profile formed the basis of risk-adapted therapy protocols. High-risk patients receive complex treatment, including various combinations of chemotherapy drugs, surgical removal of the tumor, radiation and radioisotope therapy. Since the end of the 90s of the last century, immunotherapy has been introduced into clinical practice as a post-consolidation phase with the aim of affecting the minimal residual tumour mass. GD2-targeted drugs are used as a therapeutic agent for immunotherapy. An important aspect is the study of the early and late toxicity of this therapeutic method. The main side effects include fever, neuropathic pain, allergic reactions, and capillary leak syndrome. The article presents the analysis of literature data on toxic effects arising from immunotherapy (dinutuximab beta), as well and a description of clinical case report of rare specific pathology – ophthalmic complications, which include mydriasis and accommodation disorder up to paresis. The pathogenesis of these disorders is described in the literature as a parasympathetic deficiency, realized through exposure to anti-GD2 drugs, and is leveled after the end of treatment. Given the reversible nature of the disorders, the occurrence of ophthalmic complications does not require the abolition of immunotherapy, however, careful ophthalmological monitoring of the dynamics of pathological manifestations and timely symptomatic correction of the revealed changes are necessary. This information is very important not only for pediatric oncologists/hematologists, but also for ophthalmologists and pediatricians.

11 February 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
GSGalina Solopova
Galina Solopova
RPR.P. Pirumova
R.P. Pirumova
GGG.D. Guseva
G.D. Guseva
NMN.V. Miakova
N.V. Miakova
GNG.A. Novichkova
G.A. Novichkova
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.

15 April 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
ARA.A. Roppelt
A.A. Roppelt
DYD.V. Yukhacheva
D.V. Yukhacheva
PDP.E. D’yakonov
P.E. D’yakonov
IHI.G. Hamin
I.G. Hamin
ASA.Yu. Shcherbina
A.Yu. Shcherbina
Rapid desensitization therapy (RDT) is a drug administration procedure when temporary tolerance to the medication can be reached within several hours. The method is based on the stepwise administration of increasing doses of the medication, starting from minimal dose until the total target dose is achieved. RDT is widely used when a severe allergic reaction (up to anaphylaxis) develops to a vital irreplaceable drug. The RDT procedure has proven to be effective and safe with the use of chemotherapy drugs, monoclonal antibody drugs, certain antibiotics, and enzyme replacement therapy. The article presents the first Russian case of RDT to imiglucerase in a patient with Gaucher disease and an anaphylactic reaction to imiglucerase.